🧬

Cardiogenetics

A single positive result here is rarely just one person's diagnosis.

Order a hereditary cancer panel and the result belongs mostly to the patient in front of you. Order a cardiogenetic panel and a positive result opens a conversation about first-degree relatives, cascade testing, and family members who have never set foot in your clinic. A low-confidence variant doesn't just sit in one chart — it can end up driving testing decisions across a whole family tree.

ONE RESULT, MANY CHARTS Proband Patient tested First-degree relatives Extended family None of whom ordered the test.
A positive cardiogenetic result reaches outward. Cascade testing brings relatives into the conversation who were never patients to begin with.

Curated validity, not a wide net

ScreenMyGene's cardiogenetic panel content is curated against established gene-disease validity frameworks, keeping recommendations aligned to genes and conditions with recognized clinical significance rather than every gene that's ever been associated with a cardiac finding in the literature. In a category where a result can ripple outward to people who never asked for it, "technically detectable" and "clinically actionable" need to stay two different bars.

VALIDITY AS A FILTER Every gene ever associated with a cardiac finding curated validity Recognised clinical significance
Candidate genes fall through curated gene–disease validity. Only what clears the filter reaches a panel.

How it works for cardiogenetics specifically

1. Presentation and history extraction — Documented cardiac findings, personal history, and family history relevant to inherited cardiac conditions are pulled from the chart.

2. Gene-disease validity filtering — Candidate genes are filtered against curated validity frameworks before being considered for a panel recommendation.

3. Condition-aligned panel matching — The qualifying panel is matched to the specific inherited cardiac condition supported by the documented presentation.

4. ICD-10 and coverage check — The recommendation is anchored to a documented, matching diagnosis code and checked against Medicare LCD/NCD coverage policy.

What this catches that a broad-panel approach misses

WHAT COMES BACK Broad panel more uncertain variants Curated panel fewer, each actionable An uncertain result is not a neutral outcome when it reaches a whole family.
The tradeoff that matters most here is not sensitivity — it is what an uncertain result sets in motion.

Who this is for

See how validity-curated panels support a result that reaches beyond one chart.

Request a demo

Cardiogenetic panels built on established gene–disease validity

Inherited cardiac conditions are where panel discipline matters most: gene–disease relationships are actively curated, and a panel padded with disputed genes creates uncertain results and coverage friction. ScreenMyGene keeps cardiogenetic recommendations aligned to established validity frameworks — and because one positive result can change a whole family's screening path, getting the first order right compounds.

1 resultcan trigger cascade screening across an entire family — the highest-leverage order in genomics
ClinGen / GenCCvalidity frameworks that keep panel content aligned to established gene–disease relationships
27%of advanced genetic testing claims denied — documentation discipline is the countermeasure

Common questions

What makes a cardiogenetic panel defensible?

Panel content aligned to established gene-disease validity, an indication documented in the chart, and a specific matching ICD-10-CM code - together, before the order goes out.

What is cascade testing?

Testing biological relatives of a patient found to carry a pathogenic variant. One positive result can identify at-risk family members who were never patients - a major reason the index order deserves rigor.

Why does gene-disease validity matter for coverage?

Payers increasingly expect panels built on established relationships. Disputed-gene padding invites uncertain findings and coverage friction without improving care.

Coverage glossaryDenial preventionPlatform overview